Show simple item record

dc.contributor.authorVivanco, I
dc.date.accessioned2020-08-06T14:54:50Z
dc.date.issued2014-11
dc.identifier.citationBritish journal of cancer, 2014, 111 (11), pp. 2033 - 2038
dc.identifier.issn0007-0920
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/3919
dc.identifier.eissn1532-1827
dc.identifier.doi10.1038/bjc.2014.461
dc.description.abstractCancer cells depend on a finite number of critical signals for their survival. Oncogene addiction, that is, the acquired dependence of a cancer cell on the activity of a single oncogenic gene product, has been the basis for the targeted therapy paradigm, and operationally defines such signals. Additionally, cancer cells have altered metabolic requirements that create addictions to specific nutrients such as glucose and glutamine. In this review, I will discuss the therapeutic opportunities that these two types of molecular addictions offer, focusing on lessons learned from targeting members of the epidermal growth factor receptor family of kinases, and components of MAPK pathway. I will also discuss the challenges in simultaneously harnessing two types of molecular addictions for therapeutic benefit, and the importance of understanding not only the effects of oncogenic signal transduction on metabolism, but also the impact of metabolic states on signal transduction.
dc.formatPrint-Electronic
dc.format.extent2033 - 2038
dc.languageeng
dc.language.isoeng
dc.rights.urihttps://creativecommons.org/licenses/by-nc-sa/4.0
dc.subjectAnimals
dc.subjectHumans
dc.subjectNeoplasms
dc.subjectSignal Transduction
dc.subjectMAP Kinase Signaling System
dc.subjectDrug Resistance, Neoplasm
dc.subjectMutation
dc.subjectOncogenes
dc.subjectGenes, ras
dc.subjectMolecular Targeted Therapy
dc.subjectErbB Receptors
dc.titleTargeting molecular addictions in cancer.
dc.typeJournal Article
dcterms.dateAccepted2014-07-16
rioxxterms.versionofrecord10.1038/bjc.2014.461
rioxxterms.licenseref.urihttps://creativecommons.org/licenses/by-nc-sa/4.0
rioxxterms.licenseref.startdate2014-11
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfBritish journal of cancer
pubs.issue11
pubs.notesNot known
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Molecular Addictions
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Molecular Addictions
pubs.publication-statusPublished
pubs.volume111
pubs.embargo.termsNot known
icr.researchteamMolecular Addictionsen_US
dc.contributor.icrauthorVivanco, Igoren


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record

https://creativecommons.org/licenses/by-nc-sa/4.0
Except where otherwise noted, this item's license is described as https://creativecommons.org/licenses/by-nc-sa/4.0